AIRNA Begins Phase 1 Trial of Potential RNA-Editing Therapy

Biotech firm launches first-in-human study of AIR-001 to treat rare and common conditions

Apr. 7, 2026 at 5:55pm

Got story updates? Submit your updates here. ›

A ghostly, translucent X-ray image revealing the complex, branching structure of an RNA molecule, glowing with an otherworldly blue light against a dark backdrop, conceptually representing the potential of RNA-editing therapies.AIRNA's RNA-editing therapy aims to precisely correct genetic defects, offering hope for patients with rare and common inherited diseases.Cambridge Today

AIRNA, a biotech company developing RNA-editing therapeutics, has announced the first patient has been dosed in a Phase 1 clinical trial of its lead candidate AIR-001. The therapy aims to transform the lives of patients with rare and common conditions through innovative RNA-editing technology.

Why it matters

RNA editing is an emerging field with the potential to address a wide range of inherited diseases by directly correcting genetic defects. AIRNA's pioneering work in this area could lead to functional cures for patients living with rare conditions like alpha-1 antitrypsin deficiency (AATD).

The details

The Phase 1 trial of AIR-001 will evaluate the safety, tolerability, and pharmacokinetics of the investigational RNA-editing therapy in healthy volunteers. AIRNA plans to further develop AIR-001 to treat both rare and common conditions by precisely editing RNA to restore normal gene function.

  • The first patient was dosed in the Phase 1 trial on April 7, 2026.

The players

AIRNA

A biotech company pioneering RNA-editing therapeutics to transform the lives of patients with rare and common conditions.

Got photos? Submit your photos here. ›

The takeaway

AIRNA's advancement of its pioneering RNA-editing therapy into human trials represents an important milestone in the development of potentially transformative treatments for rare and common genetic disorders.